227 related articles for article (PubMed ID: 22512635)
1. Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.
Tsirigotis P; Or R; Resnick IB; Shapira MY
Immunotherapy; 2012 Apr; 4(4):407-24. PubMed ID: 22512635
[TBL] [Abstract][Full Text] [Related]
2. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
[TBL] [Abstract][Full Text] [Related]
5. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
Hashimoto D; Merad M
Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
[TBL] [Abstract][Full Text] [Related]
6. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
7. Exploiting beneficial alloreactive T cells.
Barber LD; Madrigal JA
Vox Sang; 2006 Jul; 91(1):20-7. PubMed ID: 16756597
[TBL] [Abstract][Full Text] [Related]
8. Roles of transforming growth factor-β in graft-versus-host and graft-versus-tumor effects.
Carli C; Giroux M; Delisle JS
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1329-40. PubMed ID: 22326303
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic pathways in haematopoietic stem-cell transplantation.
van den Brink MR; Burakoff SJ
Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
[TBL] [Abstract][Full Text] [Related]
10. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease.
Sackstein R
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):2-8. PubMed ID: 16399577
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.
Goldstein SC; Porter DL
Expert Rev Hematol; 2010 Jun; 3(3):301-14. PubMed ID: 21082981
[TBL] [Abstract][Full Text] [Related]
12. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
14. Haematopoietic cell transplantation as immunotherapy.
Appelbaum FR
Nature; 2001 May; 411(6835):385-9. PubMed ID: 11357147
[TBL] [Abstract][Full Text] [Related]
15. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
16. Immunobiology of allogeneic hematopoietic stem cell transplantation.
Welniak LA; Blazar BR; Murphy WJ
Annu Rev Immunol; 2007; 25():139-70. PubMed ID: 17129175
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Selective depletion strategies in allogeneic stem cell transplantation.
Mielke S; Solomon SR; Barrett AJ
Cytotherapy; 2005; 7(2):109-15. PubMed ID: 16040390
[TBL] [Abstract][Full Text] [Related]
20. Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting.
Le NT; Chen BJ; Chao NJ
Cytotherapy; 2005; 7(2):126-33. PubMed ID: 16040391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]